Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 12, 2020
Source ID
10.1080/15384047.2020.1824989

Entities

People

  • Carl G. Maki
  • Daeun Shim
  • Lei Duan
  • Ricardo E. Perez
  • Sarah Calhoun
  • Victor V. Levenson

Organizations

  • National Cancer Institute
  • Rush University
  • United States Department of Defense